Growth Metrics

Lucid Diagnostics (LUCD) EBIT Margin (2021 - 2025)

Lucid Diagnostics' EBIT Margin history spans 5 years, with the latest figure at 1563.13% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 259697.0% year-over-year to 1563.13%; the TTM value through Dec 2025 reached 257.68%, up 80199.0%, while the annual FY2025 figure was 259.19%, 80045.0% up from the prior year.
  • EBIT Margin reached 1563.13% in Q4 2025 per LUCD's latest filing, up from 979.92% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 4092.52% in Q2 2021 to a low of 18917.11% in Q3 2022.
  • Average EBIT Margin over 5 years is 3379.88%, with a median of 1283.96% recorded in 2023.
  • Peak YoY movement for EBIT Margin: plummeted -1566211bps in 2022, then soared 1749590bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 3747.0% in 2021, then tumbled by -257bps to 13370.54% in 2022, then skyrocketed by 92bps to 1101.25% in 2023, then increased by 6bps to 1033.83% in 2024, then soared by 251bps to 1563.13% in 2025.
  • Per Business Quant, the three most recent readings for LUCD's EBIT Margin are 1563.13% (Q4 2025), 979.92% (Q3 2025), and 948.67% (Q2 2025).